INM InMed Pharmaceuticals Inc.
USHealthcareAs of 2026-07-10 16:00
Why INM matters now
InMed Pharmaceuticals Inc. (INM) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.64 with -1.20% on the session and $3.0M in market capitalization; recent performance reads 1-month -6.88% and YTD +40.57%.
The latest financial table shown here is Q3 2026, with revenue of $0.00, net income of $-3.0M, and EPS of $-0.73. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -334.0%.
The latest indexable market news headline is "Are ESI, INM, HUN, OLN Obtaining Fair Deals for their Shareholders?" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $—; recent insider activity includes Vivo Opportunity, LLC filing P-Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.88
P/S
0.67
EV/EBITDA
0.22
DCF Value
$-10.76
FCF Yield
-334.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
30.4%
Operating Margin
-246.8%
Net Margin
-246.4%
ROE
-72.7%
ROA
-108.5%
ROIC
-135.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $0.00 | $-3.0M | $-0.73 |
| Q2 2026 | $1.1M | $-2.8M | $-703.84 |
| Q1 2026 | $1.1M | $-1.7M | $-436.75 |
| Q4 2025 | $1.8M | $-2.4M | $-1.22 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
CA
Exchange
—
Beta
0.97
InMed Pharmaceuticals Inc. operates as a clinical-stage pharmaceutical firm, concentrating its efforts on the investigation and creation of therapeutic solutions derived from cannabinoids. Its primary product, INM-755, is a cannabinol-infused topical cream that is currently progressing through its second Phase I clinical trial for the management of epidermolysis bullosa. Beyond this lead candidate, the company is also developing INM-088, which is undergoing preclinical studies for glaucoma treatment, and INM-405, intended for pain relief. Its broader development pipeline encompasses cannabinoid-based interventions for a variety of medical conditions, with a particular focus on dermatological and ocular disorders. Furthermore, InMed is involved in critical IND-enabling pharmacology and preclinical toxicology research. It is also pioneering IntegraSyn, an innovative integrated biosynthesis approach designed to produce pharmaceutical-grade cannabinoids efficiently. The company maintains a research partnership with BayMedica Inc. to collaborate on the formulation and assessment of novel cannabinoid therapeutics. Established in 1981, the company is headquartered in Vancouver, Canada. It operated under the name Cannabis Technologies Inc. before officially rebranding as InMed Pharmaceuticals Inc. in October 2014.